Jin Medical International Ltd. (ZJYL) AI Stock Analysis
ZJYL AI stock analysis summary
AI ResearchJin Medical International Ltd. (ZJYL) designs, manufactures, and distributes mobility and healthcare aids, including wheelchairs and oxygen concentrators. Over the trailing twelve months, revenue reached $19.7M with an operating margin of -7.2% and EPS of $0.19. The company maintains a net cash position of $9.5M, but free cash flow was -$3.7M in FY2025.
- Market cap
- $155.3M
- Revenue (TTM)
- $19.7M
- P/E
- 10.9x
- 1Y return
- -67.8% S&P 500 16.8%
- Avg. target
- —
Bull case
- Trailing price-to-earnings stands at 10.9x, trading below the US-listed Healthcare peer median of 24.6x.
- The balance sheet carries $9.5M in net cash as of June 30, 2026, supported by a current ratio of 1.95.
- The company has beaten EPS expectations in 3 of the last 4 quarters.
Bear case
- Trailing twelve-month operating margin is -7.2%, below the peer median of 14.0%.
- Free cash flow remained negative for a second consecutive year at -$3.7M in FY2025.
- The stock declined 67.8% over the past year, trailing the S&P 500 return of 16.8%.
What Jin Medical International does
Headquartered in Changzhou, China, Jin Medical International Ltd. specializes in designing, developing, manufacturing, and distributing products for individuals with disabilities or impaired mobility. Founded in 2006 and operating as a subsidiary of Jolly Harmony Enterprises Limited, the company provides wheelchairs, oxygen concentrators, bathing machines, and various living aids. It serves domestic and international markets with healthcare and mobility equipment tailored to improve independence and daily living standards.
Growth and profitability
Revenue increased from $20.8M in FY2021 to a peak of $23.5M in FY2024, before declining 12.0% to $20.7M in FY2025. Gross margin shrank to 29.2% in FY2025 from 40.4% in FY2024, while operating margin fell to 2.9% and net income totaled $1.2M. Over five years from FY2020 to FY2025, revenue generated a compound annual growth rate of 5.0%. In the trailing twelve months ending June 30, 2026, revenue stood at $19.7M with an operating margin of -7.2% and a profit margin of 5.9%. For the latest quarter ended June 30, 2026, quarterly revenue fell 9.7% year-over-year and quarterly earnings decreased 32.0%.
Balance sheet and cash flow
As of June 30, 2026, Jin Medical held $30.1M in cash and short-term investments against total debt of $20.6M, resulting in net cash of $9.5M. Total assets were $55.8M and shareholders' equity was $30.3M, yielding a debt-to-equity ratio of 0.68 and a current ratio of 1.95. In FY2025, operating cash flow reached $2.9M, while capital expenditures of $6.6M resulted in free cash flow of -$3.7M. Over the last five years, the share count changed by -94.2%.
Valuation and performance
At $2.08 per share, Jin Medical carries a market capitalization of $155.3M and an enterprise value of $141.6M. Its trailing price-to-earnings ratio is 10.9x, compared to the median of 24.6x for its US-listed Healthcare peers. The company's price-to-sales ratio of 7.9x is higher than the peer median of 4.1x, and its EV/EBITDA stands at 194.2x versus the peer median of 12.0x. Over the past year, ZJYL returned -67.8%, while the S&P 500 (SPY) returned 16.8%.
What analysts expect
Jin Medical has exceeded analyst EPS expectations in 3 of the last 4 quarters. No analyst price targets, recommendations, or forward consensus revenue and earnings estimates are reported. Over the trailing twelve months, diluted earnings per share reached $0.19, down from $0.51 in FY2021. The stock trades with a beta of 7.41 and is 16.1% below its 200-day moving average.
Key risks and what to watch
- Quarterly revenue fell 9.7% and quarterly earnings dropped 32.0% year-over-year in the period ended June 30, 2026.
- Enterprise value to EBITDA is elevated at 194.2x compared to the sector peer median of 12.0x.
- The stock exhibits high price volatility, indicated by a beta of 7.41.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ZJYL AI stock analysis
This page is an AI-written research summary of Jin Medical International Ltd. (ZJYL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ZJYL income statement, ZJYL balance sheet, ZJYL key metrics, ZJYL chart. See the ZJYL stock overview for the latest quote and news.
ZJYL AI stock analysis FAQ
What products does Jin Medical International Ltd. produce?
Jin Medical designs, manufactures, and distributes mobility and living aids, such as wheelchairs, oxygen concentrators, and bathing machines, primarily for individuals with disabilities or impaired mobility.
What is Jin Medical's current financial leverage?
As of June 30, 2026, the company held $30.1M in cash and short-term investments and $20.6M in total debt, leaving net cash of $9.5M with a debt-to-equity ratio of 0.68.
Does Jin Medical pay a dividend?
Jin Medical does not currently pay a dividend.
Who owns Jin Medical International Ltd.?
Insiders own 12.0% of the company, institutional ownership is reported at 0.0%, and short interest represents 0.1% of the float. The company is a subsidiary of Jolly Harmony Enterprises Limited.